-

Tempus Announces Agreement With the United States Department of Veterans Affairs National Precision Oncology Program To Expand Access to Genomic Testing for Veterans With Cancer

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year agreement with the United States Department of Veterans Affairs (VA) National Precision Oncology Program (NPOP) designed to expand access to Tempus’ portfolio of next-generation sequencing offerings to support physicians in delivering personalized treatment approaches for their patients with cancer. The Veterans Health Administration is the largest integrated health system in the U.S., providing care to more than nine million Veterans annually.

The NPOP is leveraging Tempus’ broad range of comprehensive molecular profiling capabilities in an effort to improve patient outcomes with precision medicine. As part of the collaboration, providers across the VA’s 171 Medical Centers can leverage Tempus’ next-generation sequencing tests, including its solid tumor/normal assay and liquid biopsy assay. In the event of insufficient tumor tissue, Tempus offers a conversion option to a blood-based liquid biopsy test which seamlessly delivers genomic results without a delay to the clinician or the patient.

“Our AI-enabled tests combine high-quality and comprehensive genomic data with clinical data for each patient being sequenced, which allows physicians to make truly personalized decisions as they seek the optimal therapy for their patients,” said Eric Lefkofsky, Founder and CEO of Tempus. “We look forward to supporting the VA as they expand access to precision medicine solutions in oncology care to those who have served our country and deserve the very best care we have to offer.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit www.tempus.com.

Contacts

Erin Carron
Sr. Director of Communications
erin.carron@tempus.com

Tempus


Release Versions

Contacts

Erin Carron
Sr. Director of Communications
erin.carron@tempus.com

More News From Tempus

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration with researchers from Microsoft, can perform clinically important diagnostic tasks using simple prompts and can be leveraged for a variety of downstream applications. The results were published in Nature Medici...

Tempus Reports Second Quarter 2026 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026. “Q2 was another exceptional quarter for us,” said Eric Lefkofsky, Founder and CEO of Tempus. “Our strategy is working given the investments we have made in AI over the past several years are driving some of the best growth rates we have seen in our two largest businesses - Oncology Diagnostic...

Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, delivering advanced genetic insights to optimize medication safety, dosing and toxicity risk assessment. Following its acquisition of OneOme in November 2025, Tempus has fully integrated these capabilities to expand its comprehensive precision medicine po...
Back to Newsroom